###begin article-title 0
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
The Common P446L Polymorphism in GCKR Inversely Modulates Fasting Glucose and Triglyceride Levels and Reduces Type 2 Diabetes Risk in the DESIR Prospective General French Population
###end article-title 0
###begin p 1
###xml 46 76 46 76 <email xmlns:xlink="http://www.w3.org/1999/xlink">martine.vaxillaire@good.ibl.fr</email>
Corresponding author: Dr. Martine Vaxillaire, martine.vaxillaire@good.ibl.fr
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 462 466 462 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
OBJECTIVE- Hepatic glucokinase (GCK) is a key regulator of glucose storage and disposal in the liver, where its activity is competitively modulated, with respect to glucose, by binding to glucokinase regulatory protein (GCKR) in the presence of fructose 6-phosphate. Genome-wide association studies for type 2 diabetes identified GCKR as a potential locus for modulating triglyceride levels. We evaluated, in a general French population, the contribution of the GCKR rs1260326-P446L polymorphism to quantitative metabolic parameters and to dyslipidemia and hyperglycemia risk.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 81 93 <span type="species:ncbi:9606">participants</span>
RESEARCH DESIGN AND METHODS- Genotype effects of rs1260326 were studied in 4,833 participants from the prospective DESIR (Data from an Epidemiological Study on the Insulin Resistance syndrome) cohort both at inclusion and using the measurements at follow-up.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 114 115 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 124 127 124 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;13</sup>
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 175 177 175 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 252 253 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 262 264 262 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;8</sup>
###xml 319 320 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 329 331 329 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 454 455 454 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 464 466 464 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 544 545 544 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 588 592 588 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 610 613 610 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCK</italic>
###xml 663 664 663 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 673 676 673 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;13</sup>
###xml 692 693 692 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 702 704 702 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 731 732 731 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 741 743 741 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
RESULTS- The minor T-allele of rs1260326 was strongly associated with lower fasting glucose (-1.43% per T-allele; P = 8 x 10-13) and fasting insulin levels (-4.23%; P = 3 x 10-7), lower homeostasis model assessment of insulin resistance index (-5.69%; P = 1 x 10-8), and, conversely, higher triglyceride levels (3.41%; P = 1 x 10-4) during the 9-year study. These effects relate to a lower risk of hyperglycemia (odds ratio [OR] 0.79 [95% CI 0.70-0.88]; P = 4 x 10-5) and of incident cases during the study (hazard ratio [HR] 0.83 [0.74-0.95]; P = 0.005). Moreover, an additive effect of GCKR rs1260326(T) and GCK (-30G) alleles conferred lower fasting glycemia (P = 1 x 10-13), insulinemia (P = 5 x 10-6), and hyperglycemia risk (P = 1 x 10-6).
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
###xml 12 16 12 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
CONCLUSIONS-GCKR-L446 carriers are protected against type 2 diabetes despite higher triglyceride levels and risk of dyslipidemia, which suggests a potential molecular mechanism by which these two components of the metabolic syndrome can be dissociated.
###end p 6
###begin p 7
Published ahead of print at  on 12 June 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 235 236 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 574 575 571 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
The enzyme glucokinase (GCK) is the major glucose sensor of the pancreatic beta-cells, where it adapts insulin secretion to blood glucose levels. GCK also participates in regulating glycogen synthesis and gluconeogenesis in the liver (1). GCK activity is allosterically controlled in hepatocytes by the glucokinase regulatory protein (GCKR), which reversibly binds to GCK and inhibits its activity in the presence of fructose 6-phosphate. GCKR acts as a competitive inhibitor of GCK with respect to glucose and is suppressed by the specific metabolite fructose 1-phosphate (2).
###end p 9
###begin p 10
###xml 182 183 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 184 185 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 516 517 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 546 549 546 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCK</italic>
###xml 691 692 691 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 693 694 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 729 733 729 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 822 823 822 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 824 825 824 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 18 22 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 313 317 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 814 820 <span type="species:ncbi:9606">humans</span>
In GCKR-deficient mice, the disruption of this regulation and the subsequent decrease in GCK activity leads to altered glucose metabolism and impaired postprandial glycemic control (3,4), although no change in fasting blood glucose concentration is observed. Adenoviral-mediated hepatic overexpression of GCKR in mice with high-fat diet-induced diabetes improves fasting and glucose-induced glycemia and leads to a concomitant increase in insulin sensitivity and triglyceride levels and a decrease in leptin levels (5). Heterozygous mutations in GCK resulting in a reduction of enzymatic activity are responsible for a subtype of monogenic diabetes (maturity-onset diabetes of the young-2) (1,6). Previous genetic studies at the GCKR locus have not reported intragenic mutations associated with type 2 diabetes in humans (7,8).
###end p 10
###begin p 11
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 371 372 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 459 460 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 460 461 460 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 493 497 493 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 604 605 604 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 795 796 795 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 807 809 807 809 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 1047 1049 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
The Diabetes Genetics Initiative (DGI) genome-wide association study for type 2 diabetes and quantitative metabolic traits reported an intronic polymorphism of GCKR (rs780094) explaining interindividual variability in plasma triglyceride (TG) levels and a trend toward association with lower fasting glycemia, less insulin resistance, and lower risk for type 2 diabetes (9). The HapMap II CEU data () showed that rs780094 is in strong linkage disequilibrium (r2 = 0.932) with a non-synonymous GCKR variant (Pro446Leu, rs1260326) that we previously identified by the DNA sequencing of French individuals (7). Marju Orho-Melander and colleagues recently communicated their fine-mapping data showing the strongest signal for TG levels at the coding single nucleotide polymorphism (SNP) (rs1260326; P = 1.5 x 10-9), with lesser associations to fasting glycemia and insulin sensitivity (M. Orho-Melander, O. Melander, V. Lyssenko, for the DGI, unpublished data). Similar findings for the intronic variant rs780094 were reported in a Danish population (10).
###end p 11
###begin p 12
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 413 416 413 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCK</italic>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 585 589 585 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 610 613 610 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCK</italic>
We evaluated the association between GCKR rs1260326-P446L and TG levels in a middle-aged general French population with a follow-up of 9 years (11). Given the key role of GCKR in hepatic glucose metabolism, we also assessed the effect of rs1260326 on glucose homeostasis parameters and on the risk of impaired fasting glycemia and type 2 diabetes. Furthermore, as we previously showed a strong association of the GCK (-30A) promoter variant (rs1799884) to increased fasting glycemia and type 2 diabetes risk in the same study cohort (11), we also assessed possible additive effects of GCKR rs1260326-P446L and GCK -30G/A SNPs on fasting glucose, insulin, TG levels, and hyperglycemia risk.
###end p 12
###begin title 13
RESEARCH DESIGN AND METHODS
###end title 13
###begin p 14
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
Participants in the Data from an Epidemiological Study on the Insulin Resistance syndrome (DESIR) study were clinically and biologically evaluated at inclusion and at 3-, 6-, and 9-year follow-up visits (11,12). All subjects included in the study signed an informed consent form, and the protocol was approved by the ethics committee of Bicetre Hospital. Because ethnic origin could not be legally documented at the beginning of the DESIR study, the proportion of subjects having non-European ancestry was estimated as 0.30% by a STRUCTURE analysis of 328 SNPs in 654 selected subjects, as previously published (11). Moreover, all individuals born outside France were excluded from this study. Overall, 4,833 individuals of the DESIR cohort were analyzed, of whom 3,877 were examined during the entire 9-year study.
###end p 14
###begin p 15
Glycemic status was defined according to 1997 American Diabetes Association criteria: normoglycemia, defined as fasting plasma glucose (FPG) <6.1 mmol/l without hypoglycemic treatment; impaired fasting glucose (IFG), defined as FPG between 6.1 and 6.99 mmol/l without hypoglycemic treatment; and type 2 diabetes, defined as FPG >/=7.0 mmol/l and/or treatment with antidiabetic agents.
###end p 15
###begin p 16
###xml 263 265 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 266 268 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 124 127 <span type="species:ncbi:9606">men</span>
###xml 147 152 <span type="species:ncbi:9606">women</span>
Dyslipidemia was defined according to World Health Organization criteria: TG >/=1.7 mmol/l, HDL cholesterol <0.9 mmol/l for men or <1.0 mmol/l for women, or current treatment with lipid-lowering drugs. Biological parameters were assessed as previously described (11,12).
###end p 16
###begin title 17
SNP genotyping.
###end title 17
###begin p 18
###xml 315 316 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 382 384 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
Genotyping of rs1260326 was performed using TaqMan Technology (Applied Biosystems, Foster City, CA). A successful genotyping rate of 99% was achieved in the whole cohort sample. Duplicate samples were assayed with a concordance rate >/=99%. The genotype distribution of rs1260326 was in Hardy-Weinberg equilibrium (P > 0.05). The rs1799884 SNP was genotyped as previously reported (11).
###end p 18
###begin title 19
Statistical analyses.
###end title 19
###begin p 20
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
The effect of the rs1260326 genotype on quantitative parameters was assessed in untreated individuals both at baseline and using repeated measures at 3-, 6-, and 9-year follow-up visits (11). All quantitative traits were log transformed before analyses and adjusted for age, sex, and BMI. We used linear regression models for analyses at baseline and mixed models for analyses of repeated measures.
###end p 20
###begin p 21
The risk of hyperglycemia, type 2 diabetes, and dyslipidemia at the end of the study was assessed by logistic regression models, including age, sex, and BMI as covariates. Cox proportional hazards regression models were used to estimate the genotype effects on the incidence of hyperglycemia, type 2 diabetes, and dyslipidemia. The models included sex and BMI as covariates. Mean BMI was estimated for all available measures for censored individuals and for all available measures before diagnosis for case subjects. Survival time was considered equivalent to an individual's age.
###end p 21
###begin p 22
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 42 45 42 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCK</italic>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 577 581 577 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 612 615 612 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCK</italic>
The additive effect of GCKR rs1260326 and GCK (-30G/A) rs1799884 on FPG, insulin, and TG levels was assessed in individuals untreated at baseline by a linear regression model including the number of risk alleles, age, sex, and BMI as covariates in order to quantify the combined genotype effect per supplementary at-risk allele (as previously described [11]). In the same way, the additive effect of both variants on the risk of hyperglycemia at the end of the 9-years' follow-up was explored using a logistic regression model. In these analyses, we considered the T-allele of GCKR rs1260326 and the G-allele of GCK rs1799884 as protective against hyperglycemia and type 2 diabetes. We then compared the models, including the number of risk alleles as a covariate to the null model including no SNP covariate, by using likelihood ratio. All statistical analyses were performed using R (version 2.6.0) combined with mgcv, survival, and nlme packages.
###end p 22
###begin title 23
RESULTS
###end title 23
###begin p 24
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 436 437 436 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 446 448 446 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 450 457 450 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 519 520 519 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 529 531 529 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 533 540 533 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 617 624 617 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 67 79 <span type="species:ncbi:9606">participants</span>
The GCKR rs1260326-P446L variant was genotyped in a total of 4,833 participants of the DESIR study and showed an overall minor allele frequency of 43.9%. We first analyzed the relationship of rs1260326 with lipid and glucose homeostasis parameters in 4,363 individuals who were not treated with hypoglycemic or lipid-lowering drugs at inclusion. The minor T-allele of rs1260326 was associated with increased TG levels both at baseline (P = 5 x 10-4; Table 1) and from the repeated measures during the 9-year follow-up (P = 1 x 10-4; Table 2). No associations were observed with total, HDL, or LDL cholesterol levels (Table 1).
###end p 24
###begin p 25
###xml 83 84 83 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 93 95 93 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 124 125 124 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 134 136 134 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 218 219 218 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 228 230 228 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 245 252 245 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 382 383 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 392 395 392 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;13</sup>
###xml 405 406 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 415 417 415 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 435 436 435 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 445 447 445 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;8</sup>
###xml 462 469 462 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 594 598 591 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 929 936 926 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
Conversely, the same T-allele of rs1260326 was strongly associated with lower FPG (P = 9 x 10-9) and fasting serum insulin (P = 5 x 10-5) and a lower homeostasis model assessment of insulin resistance (HOMA-IR) index (P = 4 x 10-6) at baseline (Table 1). The genotype effect was even more significant when repeated measures over the 9-year study were analyzed for these parameters (P = 8 x 10-13 for FPG, P = 3 x 10-7 for insulin, and P = 1 x 10-8 for HOMA-IR) (Table 2). No effect on the beta-cell insulin secretion index was seen in this population, in agreement with the hypothesis that the GCKR coding variant would enhance insulin sensitivity through improved regulation of hepatic glucose metabolism. The characteristics of the 470 individuals treated with hypoglycemic and/or lipid-lowering medications or for whom data were unknown and were thus excluded from the quantitative trait analyses are shown in online appendix Table 1 (available online at ).
###end p 25
###begin p 26
###xml 172 173 172 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 182 184 182 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 318 319 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 330 337 330 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t3">Table 3</xref>
###xml 495 496 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Furthermore, the rs1260326 T-allele was strongly associated with a decreased risk of hyperglycemia in the whole cohort at the end of the study (OR 0.79 [95% CI 0.70-0.88]; P = 4 x 10-5) and with decreased incidence during the 9-year follow-up (based on 516 incident cases of hyperglycemia, HR 0.83 [95% CI 0.74-0.95]; P = 0.005) (Table 3). Similarly, the rs1260326 T-allele conferred a significantly lower risk of type 2 diabetes in this population (OR 0.79 [0.65-0.95] at the end of the study, P = 0.01).
###end p 26
###begin p 27
###xml 349 350 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 360 367 360 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t3">Table 3</xref>
###xml 488 489 486 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
With regard to dyslipidemia, according to World Health Organization criteria, 2,102 subjects showed abnormal TG or HDL cholesterol profiles or were treated with a lipid-lowering drug at least once during the study, and 2,731 remained normolipidemic. The rs1260326 T-allele was modestly associated with dyslipidemia risk (OR 1.12 [95% CI 1.02-1.22]; P = 0.01) (Table 3). When considering hypertriglyceridemia (TG >/=1.7 mmol/l) alone, a similar risk effect was observed (1.12 [1.01-1.23]; P = 0.03 [data not shown]).
###end p 27
###begin p 28
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 71 74 71 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCK</italic>
###xml 239 240 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 249 252 249 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;13</sup>
###xml 261 262 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 255 262 255 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 325 326 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 335 337 335 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 430 431 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 440 442 440 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 451 452 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 445 452 445 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 574 575 574 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 586 589 586 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;13</sup>
###xml 611 612 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 623 625 623 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 651 652 651 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 663 665 663 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 803 806 803 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCK</italic>
###xml 818 822 818 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
We also analyzed the combined effects of GCKR rs1260326-P446L with the GCK -30G/A SNP: when comparing carriers of four risk alleles with the reference group with zero or one allele, fasting glycemia was significantly lower by 0.20 mmol/l (P = 1 x 10-13) (Fig. 1A), fasting insulinemia was significantly lower by 6.19 pmol/l (P = 5 x 10-6) (data not shown), and hyperglycemia (including type 2 diabetes) risk decreased to OR 0.49 (P = 1 x 10-6) (Fig. 1B). Models including the number of risk alleles as a covariate were significantly better than those with no SNP covariate (P = 1.5 x 10-13 for fasting glucose, P = 5.4 x 10-6 for fasting insulin, and P = 1.2 x 10-6 for hyperglycemia or type 2 diabetes risk). As expected, no additive effect on TG levels was observed when combining the risk alleles of GCK -30G/A and GCKR rs1260326-P446L.
###end p 28
###begin title 29
DISCUSSION
###end title 29
###begin p 30
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 212 213 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 530 531 530 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 670 674 670 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 776 777 776 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 860 861 860 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 743 755 <span type="species:ncbi:9606">participants</span>
Our data show that the GCKR P446L polymorphism is associated with increased TG levels in a general French population, which extends previous findings from intronic tagged SNPs in Finnish and Swedish populations (9) and in the Danish population-based Inter99 study (10). The minor T-allele of rs1260326-P446L explained 0.2% of the TG variance in our study population, showing a more modest effect than that reported in the Scandinavian samples, where the T-allele of rs780094 explained between 0.4-1.2% of the trait variance (ref. 9 and M. Orho-Melander, O. Melander, V. Lyssenko, for the DGI, unpublished data). In the Northern European populations investigated for the GCKR intronic variant, the mean BMI values were higher than in the DESIR participants (26-30 vs. 24.5 kg/m2, respectively), and the TG levels showed more variability according to genotypes (9,10). This may explain the differences in the degree of association for TG levels between the French DESIR study and other Northern European populations.
###end p 30
###begin p 31
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 349 352 349 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCK</italic>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 734 736 734 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
Conversely, the nonsynonymous rs1260326-P446L variant has a much stronger effect on the glucose homeostasis parameters in the DESIR cohort than in the Finnish, Swedish, and Danish populations, although the effects were seen in the same direction (9,10). The lower fasting glycemia in the T-allele carriers (even greater than the levels seen for the GCK -30G/A promoter variant in the same cohort [11]) is likely due to improved hepatic glucose disposal and insulin sensitivity; this may result from a direct effect on the hepatic glucose metabolism, as GCKR closely interacts with GCK in the hepatocytes, depending on glucose concentrations, to regulate the amount and activity of GCK and, consequently, the hepatic glucose disposal (13).
###end p 31
###begin p 32
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 150 154 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 165 168 165 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCK</italic>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 643 646 643 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCK</italic>
###xml 809 811 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 420 425 <span type="species:ncbi:9606">human</span>
Whatever the mechanism of action of GCKR genetic variation, it leads to a lower risk of fasting hyperglycemia and type 2 diabetes in this study. Both GCKR-P446L and GCK -30G/A SNPs strongly modulate FPG, with significant additive effects (they lower FPG by 0.20 mmol/l in the general population and decrease hyperglycemia risk), supporting the hypothesis that these frequent variants may have a non-negligible impact on human health. Indeed, there is strong evidence that even small changes in FPG, well below the IFG threshold of 6.1 mmol/l, may be associated with risk of cardiovascular morbidity and mortality (14-16). In this context, the GCK (-30A) allele was previously shown to be associated with type 2 diabetes and increased risk for coronary heart diseases in both diabetic and nondiabetic samples (17).
###end p 32
###begin p 33
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 253 256 <span type="species:ncbi:10116">rat</span>
###xml 371 376 <span type="species:ncbi:9606">human</span>
###xml 381 384 <span type="species:ncbi:10116">rat</span>
It is tempting to propose that the P446L variant replacing a residue conserved between mammals might be the causative variant. However, one previous study having investigated the sensitivity of the GCKR-L446 mutant to fructose 6- and 1-phosphate, using rat GCKR, did not report any effect compared with the wild-type protein (7). Differential regulatory features between human and rat GCKR (18) could have masked a functional consequence of the L446 variant, or a more subtle, distinct defect acting on either GCK or another target protein remains to be discovered. Alternatively, other SNPs may be etiological, as the common P446L variant lies in a large haplotype block covering at least 400 Kb of genomic sequence ().
###end p 33
###begin p 34
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 500 504 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
In conclusion, our study in the DESIR prospective cohort shows that carriers of the GCKR-L446 variant have lower fasting glycemia and insulin resistance and are protected against the development of diabetes despite higher TG levels and a risk of dyslipidemia. This suggests, for the first time, a molecular mechanism by which these two components of the so-called metabolic syndrome can be dissociated. Based on rodent models, such as the adenoviral-mediated hepatic overexpression of GCK or GCKR in mice with diet-induced diabetes (5,19), more active GCKR may result in improved interaction with GCK, leading to more efficiently releasable pools of GCK enzyme, with subsequent beneficial effects on glucose metabolism but otherwise with a concomitant alteration of lipid profile.
###end p 34
###begin title 35
Supplementary Material
###end title 35
###begin title 36
Online-Only Appendix
###end title 36
###begin p 37
This study was supported in part by a grant from Association Francaise des Diabetiques and by a grant to P.F. from the European Union (Integrated Project EuroDia LSHM-CT-2006-518153 in the Framework Programme 6 [FP6] of the European Community). The DESIR study has been supported by INSERM, CNAMTS, Eli Lilly, Novartis Pharma, sanofi-aventis, INSERM (Reseaux en Sante Publique, Interactions entre les determinants de la sante), the Association Diabete Risque Vasculaire, the Federation Francaise de Cardiologie, la Fondation de France, ALFEDIAM, ONIVINS, Ardix Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, Merck Sante, Novo Nordisk, Pierre Fabre, Roche, and Topcon.
###end p 37
###begin p 38
We thank Nabila Bouatia-Naji for comments on the manuscript.
###end p 38
###begin title 39
REFERENCES
###end title 39
###begin p 40
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 36 37 36 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 43 46 43 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCK</italic>
###xml 90 91 90 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 120 121 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 132 133 132 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 253 254 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 405 406 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 590 591 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Additive effects of GCKR rs1260326 (T) and GCK rs1799884 -30G alleles on fasting glucose (A) and risk of hyperglycemia (B). Data in A are presented as means [95% CI] of fasting glucose (millimoles per liter) according to the number of risk alleles. The P value corresponds to the coefficient for the number of risk alleles in the linear regression model including age, sex, and BMI as covariates. Data in B are presented as ORs [95% CI] of hyperglycemia, defined as impaired fasting glucose or type 2 diabetes at the end of the follow-up study, according to the number of risk alleles. The P value corresponds to the coefficient for the number of risk alleles in the logistic regression model including age, sex, and BMI as covariates.
###end p 40
###begin p 41
###xml 183 187 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
###xml 48 60 <span type="species:ncbi:9606">participants</span>
Anthropometric and metabolic characteristics of participants not treated with either hypoglycemic or lipid-lowering drugs at inclusion in the study, with data stratified according to GCKR rs1260326 genotype
###end p 41
###begin p 42
###xml 25 26 23 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 59 60 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 90 91 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 185 186 179 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Data are means +/- SD or n unless otherwise indicated. The P values indicated are nominal P-values. Delta% is the percentage of variation of the trait per supplementary minor T-allele. P values and Delta% are from linear regression models adjusted for age, sex, and BMI. HOMA-B, homeostasis model assessment of beta-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; TG, triglycerides.
###end p 42
###begin p 43
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCKR</italic>
Effects of GCKR rs1260326 on TG levels and glucose homeostasis parameters using up to four repeated measurements over the 9-year follow-up study
###end p 43
###begin p 44
###xml 4 5 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 35 36 35 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 124 125 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The P values indicated are nominal P values. Delta%, percentage of variation of the trait per supplementary minor T-allele. P values and Delta% are from mixed models adjusted for age, sex, and BMI. HOMA-B, homeostasis model assessment of beta-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; TG, triglycerides.
###end p 44
###begin p 45
Association with hyperglycemia, type 2 diabetes, and dyslipidemia in the DESIR population at the end of the study and over the 9-year follow-up
###end p 45
###begin p 46
###xml 22 23 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 64 65 64 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Overall risk data are P, OR (95% CI) and incident risk data are P, HR (95% CI). Hyperglycemia and type 2 diabetes were defined according to 1997 American Diabetes Association criteria and dyslipidemia according to World Health Organization criteria. Hyperglycemia was defined as impaired fasting glucose or type 2 diabetes.
###end p 46
###begin p 47
OR from logistic regression models adjusted for age, sex, and BMI.
###end p 47
###begin p 48
HR from Cox proportional hazards models adjusted for age, sex, and BMI.
###end p 48

